Risk Stratification Using PET in HCM

Region Gävleborg25 enrolled

Overview

The overall rationale is to reduce the risk of sudden cardiac death in individuals with hypertrophic cardiomyopathy (HCM). The novel approach of this study is to correlate Positron Emission Tomography (PET) findings to ventricular arrhythmias detected by the implantable cardioverter defibrillator (ICD). This could potentially lead to an improved risk stratification of HCM patients.

Positron Emission Tomography (PET) is a functional imaging technique that utilizes radioactive tracers to gain information on physiological or pathophysiological processes in vivo. Different tracers can provide information on different processes of interest. In cardiology, metabolic processes consuming oxygen (aerobic) can be studied with 11-Carbon-Acetate, sympathetic innervation can be studied with 11-Carbon-hydroxyephedrine and using 15-Oxygen-water the myocardial blood flow. Structural information of the heart such as left ventricular mass, left ventricular volumes and wall thickness can also be calculated with PET. The aim is to correlate PET parameters and burden of ventricular arrhythmias in order to improve risk stratification in HCM.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hypertrophic Cardiomyopathy

Interventions

Positron Emission TomographyDIAGNOSTIC_TEST

Positron Emission Tomography

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hypertrophic cardiomyopathy, implantable cardioverter defibrillator, informed consent Exclusion Criteria: * Patients younger than 18 years, pregnancy, breast feeding, claustrophobia, intolerance/allergic reaction to adenosin or mannitol, severe hypotension, unstable angina pectoris, incompensated systolic heart failure, increased intracranial pressure, hypovolemia, dipyramidole.

Locations (1)

Region Gavleborg

Gävle, Sweden

RECRUITING

Outcomes

Primary Outcomes

Ventricular tachycardia (VT) vs myocardial blood flow

Ventricular tachycardia vs positron emissions tomography parameter Myocardial blood flow (MBF)

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Ventricular tachycardia (VT) vs ejection fraction

Ventricular tachycardia vs positron emissions tomography parameter ejection fraction (EF)

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Ventricular tachycardia (VT) vs mass

Ventricular tachycardia vs positron emissions tomography parameter mass

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Ventricular tachycardia (VT) vs wall thickness

Ventricular tachycardia vs positron emissions tomography parameter wall thickness

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Ventricular tachycardia (VT) vs oxygen consumption

Ventricular tachycardia vs positron emissions tomography parameter oxygen consumption (MVO2)

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Ventricular tachycardia (VT) vs sympathetic innervation

Ventricular tachycardia vs positron emissions tomography parameter sympathetic innervation (retention index)

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Ventricular tachycardia (VT) vs myocardial external efficiency

Ventricular tachycardia vs positron emissions tomography parameter myocardial external efficiency (MEE)

Central Contacts

Peter Magnusson, MD

CONTACT

+46705089407 peter.magnusson@regiongavleborg.se

Jonny Nordström, MSc

CONTACT

+46725727670 jonny.nordstrom@regiongavleborg.se

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Atrial fibrillation (AF) vs myocardial blood flow

Atrial fibrillation vs positron emissions tomography parameter myocardial blood flow

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Atrial fibrillation (AF) vs ejection fraction

Atrial fibrillation vs positron emissions tomography parameter ejection fraction (EF)

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Atrial fibrillation (AF) vs mass

Atrial fibrillation vs positron emissions tomography parameter mass

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Atrial fibrillation (AF) vs wall thickness

Atrial fibrillation vs positron emissions tomography parameter wall thickness

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Atrial fibrillation (AF) vs oxygen consumption

Atrial fibrillation vs positron emissions tomography parameter oxygen consumption (MVO2)

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Atrial fibrillation (AF) vs sympathetic innervation

Atrial fibrillation vs positron emissions tomography parameter sympathetic innervation (retention index)

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Atrial fibrillation (AF) vs myocardial external efficiency

Atrial fibrillation vs positron emissions tomography parameter myocardial external efficiency (MEE)

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Atrial fibrillation (AF) vs stroke work

Atrial fibrillation vs positron emissions tomography parameter stroke work (SW)

Time frame: History of VT since receiving an implantable defibrillator within last 15 years

Atrial size vs ventricular tachycardia

atrial diameter, volume vs ventricular tachycardia

Time frame: History of VT since receiving an implantable defibrillator within last 15 years